PLOS Global Public Health (Jan 2023)

Prevalence and risk factors of M tuberculosis infection in young people across 14 communities in Zambia and South Africa.

  • Modupe Amofa-Sekyi,
  • Ab Schaap,
  • Linda Mureithi,
  • Barry Kosloff,
  • Maina Cheeba,
  • Bxyn Kangololo,
  • Redwaan Vermaak,
  • Robynn Paulsen,
  • Maria Ruperez,
  • Sian Floyd,
  • Petra de Haas,
  • Sarah Fidler,
  • Richard Hayes,
  • Helen Ayles,
  • Kwame Shanaube,
  • TREATS study team

DOI
https://doi.org/10.1371/journal.pgph.0002077
Journal volume & issue
Vol. 3, no. 9
p. e0002077

Abstract

Read online

BackgroundFrom 2018-2021 the TB Reduction through Expanded Antiretroviral Treatment and TB Screening (TREATS) project took place in 21 Zambian and South African communities. The TREATS Incidence of TB Infection Cohort Study was conducted in adolescents and young people (AYP), aged 15-24 years in 14 communities. We describe the baseline prevalence and risk factors of Mycobacterium tuberculosis (M. tuberculosis) infection among this cohort and explore the quantitative QFT-Plus interferon gamma (IFN-γ) responses.Methods and findingsA random sample of approximately 300 AYP per community were recruited and information on TB/HIV risk factors, TB symptoms and social mixing patterns collected. QuantiFERON TB Gold Plus assay (QFT-Plus) was used to detect M. tuberculosis infection, following manufacturer's instructions. Logistic regression was used to determine factors associated with infection. 5577 eligible AYP were invited to participate across both countries, with 4648 enrolled. QFT-Plus results were available for 4529: 2552(Zambia) and 1977(South Africa). Overall, 47.6% (2156/4529) AYP had positive QFT-Plus results, the prevalence of infection in South Africa being twice that in Zambia (64.7% (1280/1977) vs 34.3% (867/2552) p0.6 IU/ml) of the assay at baseline showed no evidence of association with recent TB exposure.ConclusionThe high prevalence of infection in AYP warrants urgent action to address TB control, especially in South Africa. Further research is required to delineate antigen tube responses of the QFT-Plus assay more precisely to fully realise the benefit of the additional TB2 tube in high TB/HIV burden settings.